This site is intended for UK healthcare professionals only

Diabetes Professional Care
15-16 November 2023, Olympia London

The UK's leading event for the entire team involved in the prevention, treatment and management of diabetes and its related conditions.

Are you a UK healthcare professional?

We are unfortunately unable to allow patients to attend Diabetes Professional Care

If you would like more information on general practice or primary care, please refer to the NHS website.

Visit the NHS website


Subpage Hero


Find out how you can save the NHS £298m during online webinar

Find out how you can save the NHS £298m during online webinar
A “staggering and much needed saving” of £298m could be made to the NHS if a specific type 2 diabetes drug was given to people at risk of cardiovascular death or heart failure.

That’s according to a top consultant diabetologist who will be presenting a webinar looking at the benefits of dapagliflozin, based on the DECLARE study.

Entitled, ‘Delivering value beyond glycaemic control in type 2 diabetes’ Dr Marc Evans will host the session on Tuesday, June 30.


He said: “The main focus is to look at the data from DECLARE in terms of heart failure and kidney disease outcomes and to evaluate how this drug can provide value for money to the NHS, in terms of reduced disease morbidity.

“This is particularly relevant when you think that in the next few years, the NHS is going to be really short on money because of the recent excessive expense on COVID-19.”

The DECLARE study showed that dapagliflozin can prevent serious clinical events, particularly hospitalisation for heart failure, and possibly reduce the likelihood of progression of renal disease, among people without established atherosclerotic cardiovascular disease.

Dr Evans added that the “objective” of his presentation is to “contextualise these findings in terms of the economics for the NHS”.

We estimated annual CVD‐related healthcare costs to the NHS to total £15.7 billion in a year and end stage renal treatment costing £18,931 every six months, Dr Evans said the financial implications for the health service could be huge.

He added: “Translating the data from the study into economic savings to the NHS, suggest that in four years dapagliflozin could save 200,000 in patient bed days and 4,230 fewer years in renal therapy provision. That equates to a staggering and much needed saving of £298m.

“When you look at it like that, then introducing this drug seems like a no brainer as it’s likely to improve health outcomes for patients, while also saving a significant amount of money for our cash-strapped health service.”

Dr Marc Evans will host the session on Tuesday, June 30 at 1230pm. Prior registration is required.


View all News


Gold sponsor


Education Partner

Education Partner

Event Partner

Event Partner

Event Partner

Event Partner

Media Partner